Applied Neuro Solutions
About Applied NeuroSolutions
Applied NeuroSolutions Team
Research & Development
Filings & Stock Data
Contact Us

Company Contact: Bruce N. Barron, CEO
(847) 573-8025 ext. 240

Agency Contact: Ira Weingarten/Steve Chizzik
Equity Communications
(805) 897-1880

Hemoxymed IS NOW Applied NeuroSolutions, Inc.


Vernon Hills, IL November 25, 2003 - Applied NeuroSolutions, Inc (OTC BB: APNS) formerly Hemoxymed, Inc (OTC BB: HMYD) headquartered here, said its name change has become effective and that it begins trading tomorrow morning on the OTC Bulletin Board under its new symbol APNS.

Management invites all who may wish further information to visit the company's new website at

The new website has a number of special features including links to various published articles reporting on the development of the company’s diagnostic products and research tools; and financial links to SEC filings, current stock data, and monthly reports on volume and market-makers.

According to Bruce N. Barron, Applied NeuroSolutions Chairman and CEO, “the new name, the new symbol, and the new website are all reflective of a period of rapid change, as the company makes important progress in its efforts to develop and bring to market accurate and effective tests that can diagnose Alzheimer's disease at a very early stage."

In partnership with a team of scientists from Albert Einstein College of Medicine, Applied NeuroSolutions is developing an integrated product portfolio for the diagnosis and treatment of Alzheimer's disease.

This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the need to raise substantial additional equity capital, and the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, and potential competitive offerings. For further information, please review the company's 10-QSB and 10-KSB filings with the Securities and Exchange Commission, and visit the company's website at